NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy

1Massachusetts General Hospital, Boston, MA; 2Charles University, Prague, Czech Republic; 3Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy; 4Isala Klinieken, Zwolle, the Netherlands; 5Oncology Specialists, Niles, IL; 6Melanoma Institute Australia and University of Sydney, Sydney, Australia; 7Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel; 8 St James’s Institute of Oncology, St James’s University Hospital, Leeds, United Kingdom; 9University Hospital Essen, Essen, Germany; 10 Indiana University Health Goshen Center for Cancer Care, Goshen, IN; 11Oregon Health and Science University, Portland, OR; 12University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium; 13National Cancer Center Hospital, Tokyo, Japan; 14Novartis Pharmaceuticals Corporation, East Hanover, NJ; 15Universitatsspital Zurich, Zurich, Switzerland